Lupin Limited has entered into a licence and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex™ in Canada, expanding its central nervous system (CNS) portfolio in the North American market.
Under the agreement, Lupin will leverage its established commercial presence in Canada to introduce DeslaFlex™, an innovative antidepressant formulation developed by Spektus using its proprietary Flexitab™ oral drug-delivery platform. The product is positioned to offer enhanced flexibility in the management of Major Depressive Disorder, supporting more personalized treatment approaches.
The collaboration brings together Lupin’s commercial infrastructure and market reach in Canada with Spektus’s expertise in developing differentiated and novel pharmaceutical formulations. The partnership is also expected to serve as a foundation for potential future product launches under the alliance.
With the addition of DeslaFlex™, Lupin aims to further strengthen its CNS portfolio with physician-endorsed, value-added therapies aligned with Canada’s regulatory framework. The agreement marks a strategic step for Spektus as it transitions from product development to commercial execution in international markets.
The partnership underscores Lupin’s continued focus on expanding its specialty business globally while deepening its engagement in the Canadian healthcare landscape.
